Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

715
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
715
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

892
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
892
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

769
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
769
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CTSS regulates macrophage lipid metabolic reprogramming and white matter repair after intracerebral hemorrhage.

Journal of translational medicine·2026
Same author

Ependymal cell inflammatory activation in response to intracerebral hemorrhage.

Journal of neuroinflammation·2026
Same author

TRIM21 Exacerbates Ischemic Brain Injury by Promoting Astrocyte-Mediated Neuroinflammation via K63-Linked Ubiquitination of MDA5.

Research (Washington, D.C.)·2026
Same author

Enhancing patient care quality and safety under the hospital-wide "One Bed" model: a FMEA-based approach.

Frontiers in medicine·2026
Same author

A retrospective descriptive study on the early identification of near-miss events in nursing.

BMC health services research·2026
Same author

Porphy-based drug-delivery nanoparticles for photodynamic therapy and photoactivated cascade chemotherapy.

Journal of materials chemistry. B·2026
Same journal

Host's immune response to primary tumours and concomitant brain metastases in the central nervous system.

Contemporary oncology (Poznan, Poland)·2026
Same journal

Glioblastoma with an uncommon <i>TP53</i> mutation presenting with pleural metastasis: a case report and literature review.

Contemporary oncology (Poznan, Poland)·2026
Same journal

Retracted: Evaluation of morphology and angiogenesis of breast cancer in BALB/c mice using trypsin inhibitor from <i>Cucumis melo</i> seeds. <i>In vitro</i> and <i>in vivo</i> study.

Contemporary oncology (Poznan, Poland)·2026
Same journal

Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative review.

Contemporary oncology (Poznan, Poland)·2026
Same journal

Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy.

Contemporary oncology (Poznan, Poland)·2026
Same journal

Combined analysis of metabolomics and transcriptomics reveals new indicators for the diagnosis and prognosis of colorectal cancer.

Contemporary oncology (Poznan, Poland)·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis.

Huaping Huang1, Mei He1, Lihua Liu1

  • 1Mianyang Central Hospital, Mianyang, China.

Contemporary Oncology (Poznan, Poland)
|September 21, 2016
PubMed
Summary
This summary is machine-generated.

Vitamin E supplementation does not significantly prevent chemotherapy-induced peripheral neuropathy (CIPN). However, it shows promise in preventing cisplatin-associated neurotoxicity, warranting further research.

Keywords:
chemotherapymeta-analysisneuropathypreventionvitamin E

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

2.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

2.4K

Area of Science:

  • Oncology
  • Neurology
  • Nutritional Science

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a significant challenge for cancer patients undergoing treatment.
  • Previous studies on interventions for CIPN have yielded controversial results.
  • Vitamin E is being investigated for its potential role in mitigating CIPN.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the efficacy of vitamin E supplementation in preventing CIPN.
  • To synthesize findings from existing randomized controlled trials on vitamin E and CIPN.

Main Methods:

  • Systematic literature search of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials up to December 31, 2013.
  • Inclusion of randomized controlled trials (RCTs) with data extraction by two independent reviewers.
  • Data analysis performed using Review Manager 5.2.

Main Results:

  • Six RCTs with 353 patients were included. Vitamin E supplementation did not significantly reduce the overall incidence of CIPN (RR, 0.55; 95% CI, 0.29 to 1.05; p = 0.07), with substantial heterogeneity (I² = 77%).
  • Notably, vitamin E significantly prevented cisplatin-associated neurotoxicity (RR, 0.31; 95% CI, 0.17 to 0.58; p = 0.0002) with no heterogeneity (I² = 0%).

Conclusions:

  • Vitamin E administration does not appear to decrease the overall incidence of CIPN.
  • Further large-scale randomized controlled trials are necessary to definitively establish the role of vitamin E in CIPN prevention.
  • Vitamin E may be beneficial for preventing neurotoxicity specifically associated with cisplatin chemotherapy.